Matches in SemOpenAlex for { <https://semopenalex.org/work/W3192331567> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W3192331567 startingPage "3192" @default.
- W3192331567 abstract "Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) is the curative treatment of many hematological malignancies, but the relapse is one of the major causes of treatment failure and mortality. Previous clinical studies have shown that low-dose IL-2 was well tolerated and could lower the relapse rate in human T cell depleted allogeneic BMT. On the other hand, we also demonstrated that low-dose IL-2 could preferentially enhance regulatory T cell (Treg) and improve the symptoms of chronic GVHD (NEJM 2011,Sci Trans Med 2013). In murine bone marrow transplantation (BMT) model showed that Treg can protect from lethal GVHD while preserving graft-versus-leukemia (GVL) effect. Especially, CD62L+ Tregs has a higher capacity in suppressing GVHD than their CD62L- counterpart. Our recent study reported that exogenous low-dose IL-2 induced the expression of PD-1 on Treg preferentially and it was most evident in CD44+CD62L+central-memory Treg (Blood 2016). However, the impact of CD62L+ Treg enhanced by low-dose IL-2 on GVHD and GVL has not been well investigated. In this study, we studied the effect of exogenous IL-2 on the lymphocyte phenotypic profiles including naive- versus memory-type balance and also examined donor-derived immunity, especially GVHD and GVL, by using leukemia-bearing BMT model. Lethally irradiated B6D2F1 recipients were transplanted spleen cells and BM cells from B6 donors and 5000 IU Teceleukin (recombinant IL-2) was injected once a day for 14 days. The number of CD4+CD25+Foxp3+ Treg, CD4+CD25-Foxp3- conventional T cell (Tcon) and CD8+ T cell was compared between IL2- and vehicle-treated groups. The expressions of CD44, CD62L, CCR4, CCR7, Ki-67, PD-1, CTLA-4, LAG3, GITR, ICOS and TIM-3 in each subset were also examined. Lymphocytes profiling analysis showed that IL-2 treatment in the first 7 days resulted in the dominant expansion of effector T cells without Treg increase (Treg 0.10 vs 0.16,p=0.35, Tcon 2.83 vs 4.20, p=0.01, CD8 T cell 5.52 vs 10.4, p=0.01, million). On the contrary, the extended IL-2 treatment in the next 7 days increased CD62L+ Treg (21.5 vs 48.2 % of total Treg, p Disclosures Maeda: Toko Pharmaceutical Industries: Other: Investigational drug is provided free of charge." @default.
- W3192331567 created "2021-08-16" @default.
- W3192331567 creator A5011335347 @default.
- W3192331567 creator A5019924110 @default.
- W3192331567 creator A5025889209 @default.
- W3192331567 creator A5035641702 @default.
- W3192331567 creator A5041908676 @default.
- W3192331567 creator A5058586453 @default.
- W3192331567 creator A5061931042 @default.
- W3192331567 creator A5064838885 @default.
- W3192331567 creator A5081214876 @default.
- W3192331567 creator A5091466347 @default.
- W3192331567 date "2017-12-08" @default.
- W3192331567 modified "2023-09-29" @default.
- W3192331567 title "Early Administration of Low-Dose IL-2 Intensify Graft-Versus-Leukemia Effect without Worsening GVHD through Sequential Enhancement of Effector T Cell and CD62L+ Regulatory T Cell Subset" @default.
- W3192331567 doi "https://doi.org/10.1182/blood.v130.suppl_1.3192.3192" @default.
- W3192331567 hasPublicationYear "2017" @default.
- W3192331567 type Work @default.
- W3192331567 sameAs 3192331567 @default.
- W3192331567 citedByCount "0" @default.
- W3192331567 crossrefType "journal-article" @default.
- W3192331567 hasAuthorship W3192331567A5011335347 @default.
- W3192331567 hasAuthorship W3192331567A5019924110 @default.
- W3192331567 hasAuthorship W3192331567A5025889209 @default.
- W3192331567 hasAuthorship W3192331567A5035641702 @default.
- W3192331567 hasAuthorship W3192331567A5041908676 @default.
- W3192331567 hasAuthorship W3192331567A5058586453 @default.
- W3192331567 hasAuthorship W3192331567A5061931042 @default.
- W3192331567 hasAuthorship W3192331567A5064838885 @default.
- W3192331567 hasAuthorship W3192331567A5081214876 @default.
- W3192331567 hasAuthorship W3192331567A5091466347 @default.
- W3192331567 hasConcept C126322002 @default.
- W3192331567 hasConcept C203014093 @default.
- W3192331567 hasConcept C2776090121 @default.
- W3192331567 hasConcept C2777408962 @default.
- W3192331567 hasConcept C2778296632 @default.
- W3192331567 hasConcept C2778461978 @default.
- W3192331567 hasConcept C2779727006 @default.
- W3192331567 hasConcept C2779972918 @default.
- W3192331567 hasConcept C2908885563 @default.
- W3192331567 hasConcept C2911091166 @default.
- W3192331567 hasConcept C71924100 @default.
- W3192331567 hasConcept C79484868 @default.
- W3192331567 hasConcept C8891405 @default.
- W3192331567 hasConceptScore W3192331567C126322002 @default.
- W3192331567 hasConceptScore W3192331567C203014093 @default.
- W3192331567 hasConceptScore W3192331567C2776090121 @default.
- W3192331567 hasConceptScore W3192331567C2777408962 @default.
- W3192331567 hasConceptScore W3192331567C2778296632 @default.
- W3192331567 hasConceptScore W3192331567C2778461978 @default.
- W3192331567 hasConceptScore W3192331567C2779727006 @default.
- W3192331567 hasConceptScore W3192331567C2779972918 @default.
- W3192331567 hasConceptScore W3192331567C2908885563 @default.
- W3192331567 hasConceptScore W3192331567C2911091166 @default.
- W3192331567 hasConceptScore W3192331567C71924100 @default.
- W3192331567 hasConceptScore W3192331567C79484868 @default.
- W3192331567 hasConceptScore W3192331567C8891405 @default.
- W3192331567 hasLocation W31923315671 @default.
- W3192331567 hasOpenAccess W3192331567 @default.
- W3192331567 hasPrimaryLocation W31923315671 @default.
- W3192331567 hasRelatedWork W1970241155 @default.
- W3192331567 hasRelatedWork W2022211255 @default.
- W3192331567 hasRelatedWork W2051277340 @default.
- W3192331567 hasRelatedWork W2114734264 @default.
- W3192331567 hasRelatedWork W2206276344 @default.
- W3192331567 hasRelatedWork W2350614641 @default.
- W3192331567 hasRelatedWork W2531065150 @default.
- W3192331567 hasRelatedWork W2550272059 @default.
- W3192331567 hasRelatedWork W2550326764 @default.
- W3192331567 hasRelatedWork W2551979740 @default.
- W3192331567 hasRelatedWork W2552793268 @default.
- W3192331567 hasRelatedWork W2555216939 @default.
- W3192331567 hasRelatedWork W2559387152 @default.
- W3192331567 hasRelatedWork W2560948648 @default.
- W3192331567 hasRelatedWork W2561030788 @default.
- W3192331567 hasRelatedWork W2565347146 @default.
- W3192331567 hasRelatedWork W2565707347 @default.
- W3192331567 hasRelatedWork W2583821351 @default.
- W3192331567 hasRelatedWork W2979393532 @default.
- W3192331567 hasRelatedWork W2983647892 @default.
- W3192331567 hasVolume "130" @default.
- W3192331567 isParatext "false" @default.
- W3192331567 isRetracted "false" @default.
- W3192331567 magId "3192331567" @default.
- W3192331567 workType "article" @default.